Trusted Resources: News & Events
Latest announcements and gatherings
Meeting 5: Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action
The Committee on Addressing Sickle Cell Disease: A Strategic Blueprint and Plan for Action will hold an open session for the public on Wednesday, September 11, 2019. This open session will include a panel of industry speakers who are currently developing therapeutic and curative products for sickle cell disease. The purpose of this session is to have manufacturers share their perspectives with the committee about the range of products in development, the regulatory process, and considerations for ensuring widespread access to pipeline products. More information about this session, including agenda and speakers will be forthcoming.
+myBinderRelated Content
-
Statement on NHLBI Decision to Pause the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Si...bluebird bio, Inc. suspended its clinica...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
-
Healthy red blood cells owe their shape to muscle-like structuresRed blood cells are on a wild ride. As t...
-
How to Talk to Your Child About Hydroxyureahttps://www.youtube.com/watch?v=_apTt2j0...
-
Piedmont Health Services and Sickle Cell AgencyPiedmont Health Services and Sickle Cell...
-
Acute chest syndrome among hospitalized children with vaso-occlusive crisis: A nationwide study in the United StatesBackground: Acute chest syndrome (ACS) r...
-
Gene-Therapy Company Crispr Drops as FDA Puts Trial on HoldCrispr Therapeutics AG plunged after the...
Don’t forget to join the oneSCDvoice community!
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.